1. Home
  2. CMCO vs AUPH Comparison

CMCO vs AUPH Comparison

Compare CMCO & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CMCO
  • AUPH
  • Stock Information
  • Founded
  • CMCO 1875
  • AUPH 1993
  • Country
  • CMCO United States
  • AUPH Canada
  • Employees
  • CMCO N/A
  • AUPH N/A
  • Industry
  • CMCO Construction/Ag Equipment/Trucks
  • AUPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • CMCO Industrials
  • AUPH Health Care
  • Exchange
  • CMCO Nasdaq
  • AUPH Nasdaq
  • Market Cap
  • CMCO 430.3M
  • AUPH 1.4B
  • IPO Year
  • CMCO 1996
  • AUPH 1999
  • Fundamental
  • Price
  • CMCO $14.79
  • AUPH $12.81
  • Analyst Decision
  • CMCO Hold
  • AUPH Strong Buy
  • Analyst Count
  • CMCO 1
  • AUPH 3
  • Target Price
  • CMCO $35.00
  • AUPH $12.00
  • AVG Volume (30 Days)
  • CMCO 299.1K
  • AUPH 1.6M
  • Earning Date
  • CMCO 10-29-2025
  • AUPH 11-06-2025
  • Dividend Yield
  • CMCO 1.89%
  • AUPH N/A
  • EPS Growth
  • CMCO N/A
  • AUPH N/A
  • EPS
  • CMCO N/A
  • AUPH 0.42
  • Revenue
  • CMCO $959,221,000.00
  • AUPH $260,111,000.00
  • Revenue This Year
  • CMCO $2.95
  • AUPH $16.92
  • Revenue Next Year
  • CMCO $4.09
  • AUPH $14.43
  • P/E Ratio
  • CMCO N/A
  • AUPH $30.61
  • Revenue Growth
  • CMCO N/A
  • AUPH 25.59
  • 52 Week Low
  • CMCO $11.78
  • AUPH $6.43
  • 52 Week High
  • CMCO $41.05
  • AUPH $12.90
  • Technical
  • Relative Strength Index (RSI)
  • CMCO 50.08
  • AUPH 68.86
  • Support Level
  • CMCO $14.34
  • AUPH $12.06
  • Resistance Level
  • CMCO $14.93
  • AUPH $12.82
  • Average True Range (ATR)
  • CMCO 0.49
  • AUPH 0.37
  • MACD
  • CMCO -0.00
  • AUPH -0.04
  • Stochastic Oscillator
  • CMCO 48.15
  • AUPH 93.23

About CMCO Columbus McKinnon Corporation

Columbus McKinnon Corp is a designer, manufacturer, and marketer of intelligent motion solutions, including motion control products, technologies, automated systems, and services that efficiently and ergonomically move, lift, position, and secure materials. Its key products include hoists, crane components, precision conveyors, actuators, rigging tools, light rail workstations, and digital power and motion control systems. The company's targeted market verticals include general industries, process industries, industrial automation, and e-commerce/supply chain/warehousing among others. Geographically, the company generates a majority of its revenue from the United States and the rest from Germany, Canada, Asia Pacific, Latin America, Europe, the Middle East, and Africa.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: